For its third fiscal quarter (ending September 30), Medifast Inc. (NYSE: MED) has reported a -36% decline in E.P.S. from $3.30 a year ago to $2.12 in the current quarter. However, this result exceeded the consensus estimate of $1.07 by $1.05. E.P.S. were $11.01 for the latest four quarters through September 30 versus $13.30 for the same period a year ago — a decline of -17%.
Recent Price Action
Medifast Inc. (NYSE: MED) stock increased 1.1% on 11/6/23. The shares closed at $70.66. The stock has risen 1.6% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, MED is expected to continue to be a major Value Builder.
Medifast has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Medifast has a slightly positive Appreciation Score of 68 but a slightly negative Power Rating of 32, with the Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment